Oslo, Norway (13 February 2019) — Based on the power of attorney granted at the annual general meeting of NattoPharma ASA ("NattoPharma" or "Company") on May 30th, 2018, and the option program related to defined operational objectives approved by the Board of Directors in 2018, the Board of Directors of NattoPharma has in board proceedings February 12th, 2019 granted a total of 292 500 options to executive management, other employees and strategic partners. Options are granted based on performance against defined criteria and metrics.

The following persons on the executive management team have been granted options;

Name Granted Options Options Prior to Grant Options after Grant
Kjetil Ramsøy, CEO & CFO 100 000 125 100 225 100

Other employees and partners have been granted a total of 192 500 options.

The options have an exercise price equal the closing price on Oslo Axess on February 12th, 2019, which is equal to NOK 9,00.

The options granted are vested immediately and may be exercised up to and including March 31st, 2023.


For more information, please contact:

Kjetil Ramsøy,

CEO, NattoPharma


This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.


Documents & Links